Stay updated with breaking news from Clinical Evolution. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Earlier this week, Charles River Laboratories International, Inc. revealed its Alternative Methods Advancement Project (AMAP), which it said is a strong initiative aimed at changing drug discovery and development by exploring alternatives to animal testing.
OSP was lucky enough to talk to David Menzies (pictured), executive director, technology solutions at ICON to find out how he thinks the pharma industry needs to overcome the real-world data challenges.
David Menzies is the executive director of technology solutions at ICON, a company providing outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device, and government and public health organisations.
A £30 million ($38 million) study into liver cirrhosis, the most extensive ever conducted worldwide has been announced by Newcastle University and University of Edinburgh, funded by Boehringer Ingelheim.
Healthcare breakthroughs have long-standing barriers when it comes to unlocking the powerful insights trapped in medical imaging data.